We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Most patients (92.7%) with recurrent C. difficile ...
Please provide your email address to receive an email when new articles are posted on . Ninety-five percent of patients achieved treatment success at 8 weeks after administration of Rebyota via ...
FDA approved to prevent recurrent C. difficile infection (rCDI), REBYOTA is widely available with a strong drug supply and dedicated manufacturing facility Since launch, Ferring created REBYOTA @ Home ...
Oral presentation highlights microbiome restoration through six months with REBYOTA from Phase 3b CDI-SCOPE trial New data from CDI-SCOPE evaluating the long-term safety of REBYOTA Retrospective ...
REBYOTA is the first and only single-dose microbiome-based therapy approved by the U.S. Food and Drug Administration (FDA) for the prevention of recurrent C. difficile ( C. diff ) infection in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback